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OBJECTIVES The goal of this study was to investigate the influence of short-term external counterpulsation
(ECP) therapy on flow-mediated dilation (FMD) in patients with coronary artery disease
(CAD).
BACKGROUND In patients with CAD, the vascular endothelium is usually impaired and modification or
reversal of endothelial dysfunction may significantly enhance treatment. Although ECP
therapy reduces angina and improves exercise tolerance in patients with CAD, its short-term
effects on FMD in patients with refractory angina pectoris have not yet been described.
METHODS We prospectively assessed endothelial function in 20 consecutive CAD patients (15 males),
mean age 68  11 years, with refractory angina pectoris (Canadian Cardiovascular Society
[CCS] angina class III to IV), unsuitable for coronary revascularization, before and after
ECP, and compared them with 20 age- and gender-matched controls. Endothelium-
dependent brachial artery FMD and endothelium-independent nitroglycerin (NTG)-
mediated vasodilation were assessed before and after ECP therapy, using high-resolution
ultrasound.
RESULTS External counterpulsation therapy resulted in significant improvement in post-intervention
FMD (8.2  2.1%, p  0.01), compared with controls (3.1  2.2%, p  0.78). There was
no significant effect of treatment on NTG-induced vasodilation between ECP and controls
(10.7  2.8% vs. 10.2  2.4%, p  0.85). External counterpulsation significantly improved
anginal symptoms assessed by reduction in mean sublingual daily nitrate consumption,
compared with controls (4.2  2.7 nitrate tablets vs. 0.4  0.5 nitrate tablets, p 0.001 and
4.5 2.3 nitrate tablets vs. 4.4 2.6 nitrate tablets, p 0.87, respectively) and in mean CCS
angina class compared with controls (3.5  0.5 vs. 1.9  0.3, p 0.0001 and 3.3  0.6 vs.
3.5  0.5, p  0.89, respectively).
CONCLUSIONS External counterpulsation significantly improved vascular endothelial function in CAD
patients with refractory angina pectoris, thereby suggesting that improved anginal symptoms
may be the result of such a mechanism. (J Am Coll Cardiol 2003;42:2090–5) © 2003 by
the American College of Cardiology Foundation
Patients with symptomatic coronary artery disease (CAD)
are usually treated with conventional drug therapy including
nitrates, beta-receptor blocking agents, and calcium channel
blockers (1), or coronary revascularization when appropri-
ate, either by percutaneous transluminal coronary interven-
tion (PCI) (2) or coronary artery bypass grafting (CABG)
(2–6). However, a number of patients do not respond
satisfactorily to such therapy, or are unsuitable candidates
for invasive treatment.
See page 2096
Enhanced external counterpulsation therapy (ECPT) has
been studied for over 40 years as a noninvasive method for the
treatment of CAD (7). It may be a successful alternative
therapy for symptomatic CAD patients who are either unsuit-
able for coronary revascularization or refractory to conventional
pharmacologic treatment or repeat interventions, including
CABG and/or PCI (8–14). The exact mechanisms by which
ECPT exerts its beneficial effects are unknown, but one of its
effects is considered to be the development and recruitment of
collateral vessels (15). Recent studies suggest that shear stress
induced by ECPT might result in the release of a variety of
growth factors and the subsequent stimulation of angiogenesis
in coronary beds (16).
It is known that the vascular endothelium plays a key role in
circulatory homeostasis through its ability to regulate the
vascular milieu by the synthesis and release of biologically
active substances, such as endothelium-derived relaxing factor
(17,18). The endothelium influences not only vascular tone,
but also vascular remodeling, as well as hemostasis and throm-
bosis through platelet, coagulant, and fibrin effects (19,20). In
atherosclerotic arteries, these endothelium functions are im-
paired and potentiate an adverse pathophysiology through
increased vasoconstriction (i.e., paradoxical vasoconstriction)
(20,21) and thrombosis (20). It has been suggested that by
reducing cardiovascular risk factors, the modification or rever-
sal of endothelial dysfunction may be of significant therapeutic
benefit in the treatment of CAD (20,22).
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Over the past decade, a noninvasive technique has been
developed to evaluate endothelium-dependent, brachial ar-
tery flow-mediated dilation (FMD) (23–25). This stimulus
provokes the endothelium to release nitric oxide (NO) with
subsequent vasodilation that can be imaged and quantitated
as an index of vasomotor function. The advantages of this
high-frequency ultrasonographic imaging of the brachial
artery are two-fold; it is noninvasive and also facilitates
repeated measurements (25).
Because the impact of ECPT on endothelial function has
not yet been investigated, we designed a study to test the
impact of short-term ECPT on FMD in CAD patients
with refractory angina pectoris, unsuitable for coronary
revascularization. We hypothesized that ECPT would im-
prove FMD in CAD patients with refractory angina pec-
toris.
METHODS
Study design and population. Twenty consecutive pa-
tients were recruited from a supervised external counterpul-
sation (ECP) program at the Heart Institute of the Sheba
Medical Center and comprised the ECP group. Twenty
age- and gender-matched consecutive CAD patients who
did not want to participate in the ECP program represented
the control group. Study inclusion criteria included men and
women age 20 years with CAD documented by prior
myocardial infarction, coronary artery bypass surgery, or
coronary angiography or angioplasty. Refractory angina
pectoris (Canadian Cardiovascular Society [CCS] angina
class III or IV), obligatory in all patients and rendering them
unsuitable for coronary revascularization (either CABG or
PCI), was determined by two criteria (26): objective isch-
emia producing severe symptoms, and/or exhaustive at-
tempts of all known conventional therapies. Patients with
refractory angina (CCS angina class III or IV) had to be
either markedly limited or incapable of performing even
ordinary physical activity without discomfort. Objective
evidence of ischemia, as demonstrated by exercise treadmill
testing, stress imaging studies or coronary physiologic stud-
ies, continuing symptoms despite maximal tolerated medical
therapy, and a consensus on the lack of feasibility of
revascularization either by PCI or CABG, was considered
to be mandatory. Exclusion criteria included unstable an-
gina, congestive heart failure New York Heart Association
(NYHA) functional class II, aortic regurgitation, valvular
heart disease, acute myocardial infarction 3 months, left
main stenosis 50%, systemic hypertension 180/110 mm
Hg, permanent pacemaker, atrial fibrillation, or ventricular
premature beats that would interfere with ECP triggering,
clinically evident peripheral vascular disease, deep vein
thrombosis, phlebitis and hemorrhagic diathesis, use of
anticoagulants, pregnancy, abdominal aortic aneurysm, his-
tory of drug or alcohol abuse, chronic liver disease, or refusal
to sign the informed consent. The institutional review board
approved the study, and all participants signed the written
informed consent form.
Patients were instructed to continue taking their regular
medications and maintain their usual diet throughout the
study. Before and after a full 35-h ECP course of treatment
in the ECP group or after a 2-month period in the control
group, and after an overnight fast, patients underwent a
physical examination, brachial artery reactivity testing, CCS
angina class assessment, and were asked to list the number
of anginal episodes experienced and the number of nitro-
glycerin (NTG) tablets taken during the preceding 7 days.
The ECP system. The ECP device (CardioAssist System,
Cardiomedics, Inc., Irvine, California) contains a portable
control console containing pumps and valves and reusable
fabric cuffs that contain inflatable plastic bladders, which are
fastened with Velcro around the patient’s calves, thighs, and
buttocks. During diastole, the cuffs are sequentially inflated
first around the calves, then around the thighs, and finally
around the buttocks, and are synchronized with the patient’s
electrocardiogram. Compression of the cuffs during diastole
forces blood from the legs and buttocks up to the heart,
increasing the flow of blood through the coronary arteries to
the heart muscle. The decompression of the cuffs during
systole reduces the work effort of the heart. The pressures
applied to the cuffs range from 0 to 310 mm Hg. Blood
pressure changes are monitored by finger plethysmography.
Duration time for each full ECP course was 35 h,
extended over a 7-week period. Individual treatment ses-
sions, operating 5 days a week, lasted 1 h per session. Vital
signs were recorded at each treatment session, lower extrem-
ities were examined for areas of redness or ecchymosis,
adverse experiences were reported, the number of anginal
episodes and the number of NTG tablets taken during the
preceding 24-h period were registered. An adverse reaction
was defined as the development of any new symptom or
complaint from the time of the first ECP session.
Vascular function protocol. Endothelial function in the
form of endothelium-dependent brachial artery FMD was
measured as previously described (24,25,27,28). Briefly,
FMD was assessed in the subject’s right arm in the
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CAD  coronary artery disease
CCS  Canadian Cardiovascular Society
ECP  external counterpulsation
ECPT  external counterpulsation therapy
FMD  flow-mediated dilation
NO  nitric oxide
NTG  nitroglycerin
NYHA  New York Heart Association
PCI  percutaneous transluminal coronary
intervention
%FMD diameter percent change caused by
endothelium-dependent flow-mediated
vasodilation
%NTG  endothelium-independent percent change from
baseline in nitroglycerin-mediated vasodilation
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recumbent position in a temperature-controlled room
(220°C) after a 10-min equilibration period, by a single
ultrasonographer blinded to treatment assignment. Using a
15-6 MHz linear array (15-6L HP) ultrasound (HP
SON09-09OS 5500 CV system, Agilent Technologies Inc.,
Andover, Massachusetts), the brachial artery was longitudi-
nally imaged approximately 5 cm proximal to the antecubi-
tal crease, where the clearest image was noted. When a
reasonable image was obtained, the surface of the skin was
marked, and the arm and the ultrasound probe were kept in
the same position by the ultrasonographer throughout the
study. An electrocardiogram was monitored continuously,
and blood pressure was taken in the left arm every minute
throughout the study.
Study phases. ENDOTHELIUM-DEPENDENT FMD. Follow-
ing a 2-min baseline period, a frozen 3-cm longitudinal
image of vessel without color flow was obtained and frozen
for 5 s. The image was then unfrozen and switched to a
pulse wave Doppler for 5 s at a sweep speed of 50 mm/s. A
pneumatic tourniquet placed around the forearm proximal
to the target artery was inflated after the baseline phase to a
pressure of 50 mm Hg above the subject’s systolic blood
pressure (or until no blood flow was noticed through the
brachial artery by the Doppler probe), and this pressure was
held for 5 min. Increased flow was then induced by sudden
cuff deflation. A continuous scan was performed at defla-
tion, 60 and 90 s after cuff deflation, with frozen and
Doppler measurements recorded at similar intervals to the
baseline phase.
NTG-INDUCED (NON-ENDOTHELIUM-DEPENDENT) VASODI-
LATION. Thirteen minutes after cuff deflation, a second
2-min baseline-resting scan was recorded to confirm vessel
recovery. After the administration of a sublingual NTG
tablet (Nitrostat, 0.4 mg, Parke-Davis, New Jersey), scan-
ning was performed continuously for 5 min.
Data analysis. The ultrasound images were recorded on an
S-VHS videotape with an SLV-RS7 videocassette recorder
(SONY, California). The diameter of the brachial artery
was measured from the anterior to the posterior interface
between the media and adventitia (“m line”) at a fixed
distance (29). The mean diameter was calculated from four
cardiac cycles synchronized with the R-wave peaks on the
electrocardiogram. All measurements were made at end
diastole to avoid possible errors resulting from variable
arterial compliance (30). The internal diameter was calcu-
lated with PC Prosound software (USC, Los Angeles,
California) using a Horita Data Translation Image Process-
ing board (DT2862-60Hz; Mission Viejo, California) (24).
The diameter percent change caused by endothelium-
dependent flow-mediated vasodilation (%FMD) and
endothelium-independent percent change from baseline in
NTG-mediated vasodilation (%NTG) were expressed as
the percent change relative to that at the initial resting scan.
The intraobserver variability for repeated measurements is
0.0  0.07 mm in our laboratory.
Statistical analysis. Group data are expressed as mean 
SD. Differences between clinical characteristics and brachial
artery vasodilator responses were evaluated and analyzed by
unpaired t tests for two-group comparisons, and one-way
analysis of variance for multiple-group comparisons. Com-
parison of biochemical measurements was performed using
the unpaired Student t test and Wilcoxon signed-rank test.
The Wilcoxon-Mann-Whitney U test was used to calculate
differences over time and to compare the treatment groups.
A value of p  0.05 was considered significant.
RESULTS
Our study population was comprised of 40 CAD patients,
20 patients (15 males) in the ECP group and 20 (17 males)
in the control group, with a mean age of 68  11 years
(range 44 to 82), and mean body mass index of 26  4
kg/m2 (range 20 to 37 kg/m2) (Table 1). No significant
group differences in baseline characteristics were seen (Table
1). Baseline lipid values were within the National Choles-
terol Education Program Adult Treatment Panel III treat-
ment goal. Overall group mean low-density cholesterol at
study entry was 91  14 mg/dl (2.35 mmol/l) (range 43
[1.11] mmol/l to 132 [3.41] mmol/l). All patients had
refractory angina pectoris, and 75% had CCS angina class
IV (Table 1). There were no significant changes in concom-
itant medication use and no serious adverse effects through-
out the study.
Treatment effect on endothelial function. At baseline,
the total study population had FMD of 3.0  2.6% and
NTG-mediated vasodilation of 10.2 2.4%. There were no
significant differences at baseline FMD (Fig. 1) or NTG-
mediated dilation between the two groups. External coun-
terpulsation therapy resulted in a significant improvement in
post-intervention FMD (8.2  2.1%, p  0.01 compared
Table 1. Baseline Characteristics of Study Population
Variable
ECP Group
(n  20)
Control Group
(n  20)
Age (yrs) 68  11 67  12
Body mass index (kg/m2) 26  4 25  7
CCS angina class IV 15 (75) 14 (70)
CCS angina class III 5 (25) 6 (30)
Systemic hypertension 10 (50) 7 (35)
Diabetes mellitus 7 (35) 8 (40)
Current smoker 0 0
Hypercholesterolemia 15 (75) 16 (80)
Previous myocardial infarction 14 (70) 13 (65)
Previous coronary angioplasty 12 (60) 13 (60)
Previous coronary bypass 10 (50) 11 (55)
Beta-receptor antagonist 14 (70) 13 (65)
Calcium antagonists 9 (45) 7 (35)
Diuretics (lasix) 4 (20) 5 (25)
Aspirin 19 (95) 19 (95)
Long-acting nitrates 16 (80) 17 (85)
ACE inhibitors 13 (65) 12 (60)
Lipid-lowering agents 15 (75) 16 (80)
Values are expressed as mean  SD or n (%). All p  NS.
ACE  angiotensin-converting enzyme; CCS  Canadian Cardiovascular Soci-
ety; ECP  external counterpulsation.
2092 Shechter et al. JACC Vol. 42, No. 12, 2003
External Counterpulsation Therapy December 17, 2003:2090–5
with baseline), a finding not evident in the control group
(3.1  2.2%, p  0.78 compared with baseline) (Fig. 1). At
the end of the trial, FMD (post-intervention %FMD 
baseline %FMD divided by baseline %FMD) was signifi-
cantly higher in the ECP group compared with the control
(1.7  0.1% vs. 0.1  0.1%, p 0.01, respectively). There
was no significant effect of treatment on NTG-induced
vasodilation between the ECP and control groups (10.7 
2.8% vs. 10.2  2.4%, p  0.85, respectively).
Treatment effect on symptoms. External counterpulsation
treatment significantly improved anginal symptoms assessed
by reduction in mean sublingual nitrate consumption per
day compared with the control group (4.2  2.7 nitrate
tablets vs. 0.4  0.5 nitrate tablets, p 0.001 and 4.5  2.3
nitrate tablets vs. 4.4  2.6 nitrate tablets, p  0.87,
respectively) and improvement in mean CCS angina class
compared with the control group (3.5  0.5 vs. 1.9  0.3,
p 0.0001, and 3.3  0.6 vs. 3.5  0.5, p  0.89,
respectively) (Fig. 2). At the end of the study, no patient
from the ECP group had CCS angina class IV; 1 patient
(5%) had CCS angina class I, 17 patients (85%) had class II,
and 2 patients (10%) had class III. These two patients had
CCS angina class IV at baseline. In the control group,
however, there was no significant change in the CCS angina
class from baseline (Fig. 2).
DISCUSSION
This study demonstrates for the first time that short-term
ECP intervention compared with controls results in signif-
icant improvement of brachial artery endothelial function in
CAD patients with severe refractory chronic angina pecto-
ris. Endothelial dysfunction is not only confined to the
coronary arteries but may represent a systemic disorder that
also affects the peripheral vascular beds, including both
conduit arteries and small resistance vessels in the extrem-
ities (31). Our results reinforce the hypothesis that shear
stress induced by ECPT could lead to increased endothelial
cell production and the release of NO, a powerful mediator
of generalized vasodilation in coronary beds, leading to
improved myocardial perfusion and coronary flow reserve in
CAD patients with angina (10,15). This hypothesis is also
supported by the recent observation that sustained exercise
in dogs increased endothelial NO synthase gene expression
and coronary vascular NO production (32). Serum NO
levels, myocardial perfusion, and coronary flow reserve were
also increased by ECPT in patients with chronic stable
angina (15). Recently, Bonetti et al. (33) also demonstrated
that ECP improved endothelial function assessed by reac-
tive hyperemia peripheral arterial tonometry (a novel, non-
invasive technique to assess peripheral microvascular endo-
thelial function in the finger) in 23 symptomatic CAD
patients despite administration of optimal medical therapy.
There are several potential mechanisms that underline
the beneficial effects of ECPT in CAD patients with
refractory angina pectoris; ECPT reduces exercise-induced
myocardial ischemia (11) in association with improved left
ventricular diastolic filling and a decrease in plasma brain
natriuretic peptide levels (12); ECPT enhances the vascular
endothelium by increasing shear stress to express platelet-
derived growth factor A and B, vascular endothelial growth
factor, and fibroblast growth factor-2 from vascular smooth
muscle and endothelial cells, leading to open or enhanced
development of collateral channels (16,34) and angiogenesis
(16); ECPT decreases cardiac afterload (35).
Our current results demonstrate a significant improve-
ment in peripheral vascular endothelium-dependent FMD
in CAD patients with refractory angina pectoris, treated by
short-term ECP, suggesting that ECP-increased NO pro-
duction and release from peripheral arteries lead to a
decrease in peripheral vascular resistance (15).
In the present study, patients were used as their own
Figure 2. Bar graphs showing the beneficial effects of short-term
external counterpulsation (ECP) before (open bars) and after (closed
bars) two months of treatment on (A) mean Canadian Cardiovascular
Society (CCS) angina class, and (B) mean number of daily sublingual
nitroglycerin tablets consumed in the ECP group (n  20), compared
with no significant change in the control group (n  20) (C and D).
Data are expressed as mean  SD.
Figure 1. The percent change in endothelium-dependent brachial artery
flow-mediated vasodilation (%FMD) from baseline in external counterpul-
sation (ECP) (closed circles) (n 20) and control (open circles) (n 20)
groups at baseline and after two months.
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controls. Whereas CAD is largely unpredictable in its
course, regression would not be expected to occur over a six-
to seven-week period in a group of patients whose angina
had been disabling or progressive over a period of months or
years. The enrolled patients did not undergo any simulta-
neous therapy such as strict diet, aggressive lipid reduction,
weight loss, or a supervised exercise program. Sublingual
antianginal medications were significantly decreased during
the course of the study in all patients, and CCS angina class
significantly improved. The study cohort was predominantly
male, and, therefore, definitive conclusions regarding effi-
cacy in females should await future studies.
External counterpulsation therapy was well-tolerated by all
patients enrolled in the study. No patient withdrew after
enrollment, and there were no complications resulting from
ECPT.
Study limitations. We studied a small number of stable
CAD patients with near-optimal lipid values. In addition, it
is possible that the impact of ECP intervention on the
brachial artery FMD was underestimated due to the rela-
tively low-risk population. Following our results, further
studies are indicated comprising a larger number of CAD
patients who are at higher risk.
There is both biologic and measurement variability in the
ultrasound assessment of brachial artery FMD. However,
previous studies have demonstrated the feasibility of this
approach, if performed carefully, for detecting change in
relatively small sample sizes (24,25,36).
Perhaps the major limitation of this study is the lack of a
double-blind treatment for patients with refractory angina
pectoris.
Conclusions. In conclusion, our study demonstrates that
ECPT in CAD patients with refractory angina pectoris,
unsuitable for coronary interventions, results in significant
improvement in brachial artery endothelial function and
anginal symptoms, suggesting a potential mechanism
whereby ECPT could beneficially improve anginal
symptoms.
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